

CLAIMS

1. Use of an isolated antibody that binds to human FcRn in the manufacture of a medicament for the treatment of lupus nephritis, myasthenia gravis, chronic inflammatory demyelinating polyneuropathy (CIDP), systemic lupus, hemolytic anemia, bullous pemphigoid, chronic inflammatory demyelinating polyneuropathy, rheumatoid arthritis, Sjögren's syndrome, and autoimmune haemolytic anaemia (AIHA), the isolated antibody comprising: (1) a light chain comprising the amino acid sequence of SEQ ID NO: 19; and (2) a heavy chain comprising the amino acid sequence of SEQ ID NO: 24.
2. The use of claim 1, wherein the disorder is myasthenia gravis.
3. The use of claim 1, the disorder is autoimmune haemolytic anaemia.
4. The use of claim 1, wherein the antibody is administered at about 1 mg/kg to about 50 mg/kg.
5. The use of claim 1, wherein the isolated antibody is formulated for delivery by a method selected from the group consisting of intravenous administration, parenteral administration, subcutaneous administration, intramuscular administration, intra-arterial administration, intrathecal administration, and intraperitoneal administration.
6. The use of claim 5, wherein the delivery method is intravenous.
7. The use of claim 5, wherein the delivery method is subcutaneous.
8. The use of claim 1, wherein the isolated antibody is administered daily, weekly, monthly, biannually, or annually.
9. The use of claim 1, wherein the disorder is lupus nephritis.
10. The use of claim 1, wherein the disorder is autoimmune haemolytic anaemia (AIHA).
11. The use of claim 1, wherein the disorder is chronic inflammatory demyelinating polyneuropathy (CIDP).
12. The use of claim 1, wherein the disorder is systemic lupus.

13. The use of claim 1, wherein the disorder is bullous pemphigoid.
14. The use of claim 1, wherein the disorder is chronic inflammatory demyelinating polyneuropathy.
15. The use of claim 1, wherein the disorder is rheumatoid arthritis.
16. The use of claim 1, wherein the disorder is Sjögren's syndrome.